Metabolic Features Effects on FAST Score in MASLD Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

385 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-09-01

Study Completion Date

2025-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational cross-sectional study is to evaluate the effect of metabolic features on Fibroscan-AST (FAST) score stratification in metabolic dysfunction-associated steatotic liver disease (MASLD) patients in Egypt.

Researchers will identify the metabolic risk factors in patients with MASLD. evaluate the effect of metabolic features on stratifying MASLD patients by predicting higher FAST score.

Participants will be subjected to history taking, clinical examination, laboratory investigations, abdominal ultrasonography, and transient elastography (Fibroscan) to measure liver stiffness (LSM) and controlled attenuation parameter (CAP). The Non-alcoholic fatty liver disease (NAFLD) fibrosis score and FAST score will be calculated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MAFLD Fibrosis Score for Detecting Fibrotic NASH in MAFLD Egyptian Patients

NCT06492369

Metabolic- Associated Fatty Liver Disease (MAFLD)

COMPLETED

Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian

NCT04081571

NAFLD Insulin Resistance Hepatic Steatosis

UNKNOWN

NMR-based Metabolic Profiling Identifies High Risk of MAFLD Patients With Advanced Fibrosis

NCT05734599

Metabolic Dysfunction-associated Fatty Liver Disease Metabolic Disease

UNKNOWN

Subclinical Cardiovascular Changes in NAFLD Patient (Predictive Value of Speckle Tracking Echocardiography )

NCT05790057

Liver Steatoses

UNKNOWN

Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.

NCT06797596

Liver Fibrosis Due to NASH MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease Alcohol Liver Disease

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Dysfunction-Associated Steatotic Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

ECOLOGIC_OR_COMMUNITY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MASLD patients

385 MASLD patients who had steatosis detected by (VCTE-CAP) elastography

Transient Elastography

Intervention Type RADIATION

participants will be subjected to anthropometric measurements, laboratory investigations (complete blood count, liver and kidney functions, lipid profile, virology tests, fasting insulin, fasting sugar, 2 hour postprandial sugar, HbA1c, and HOMA-IR), radiological examination (abdominal ultrasound, Fibroscan). the NAFLD fibrosis score, APRI, FIB-4 score, and FAST score will be calculated.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transient Elastography

participants will be subjected to anthropometric measurements, laboratory investigations (complete blood count, liver and kidney functions, lipid profile, virology tests, fasting insulin, fasting sugar, 2 hour postprandial sugar, HbA1c, and HOMA-IR), radiological examination (abdominal ultrasound, Fibroscan). the NAFLD fibrosis score, APRI, FIB-4 score, and FAST score will be calculated.

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients with MASLD who had steatosis detected by (VCTE-CAP) elastography

Exclusion Criteria

* Patients with a history of significant alcohol consumption more than 30 g/day in men and \> 20 g/day in women.
* Patients with positive hepatitis B or C virus markers.
* Patients with autoimmune hepatitis.
* Patients with any other metabolic liver disease.
* Patients with hepatic focal lesions.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No